Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800 an Inhibitor of the Heat Shock Protein HSP90
-
- STATUS
- Recruiting
-
- participants needed
- 44
-
- sponsor
- Centre Hospitalier Universitaire Dijon
Summary
NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).
Details
| Condition | Acute T Lymphoblastic Leukemia (T-ALL), Acute B Lymphoblastic Leukemia (B-ALL) |
|---|---|
| Age | 18years - 80years |
| Treatment | Control, injection of BEP 800 |
| Clinical Study Identifier | NCT04437420 |
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Last Modified on | 19 February 2024 |
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.